Q-omics provides the consensus-scored ANKRD49 profile across patient tissues and cancer cell-line models. ANKRD49 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ANKRD49 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ANKRD49 RNA expression shows 19,776 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where ANKRD49 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD49 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD49 survival associations across molecular data types. ANKRD49 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD49 RNA expression–survival associations across cancer types. High ANKRD49 expression shows unfavorable associations in ACC, UVM, LIHC and LGG, but favorable associations in LUAD and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ANKRD49 RNA expression.
This table summarizes ANKRD49 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD49. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD49 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BLCA, CHOL and LUAD. The HNSC box plot shows higher ANKRD49 RNA expression in tumor versus normal tissue (log2 FC = +0.794, t-test p < 0.001).
This table shows molecular features associated with ANKRD49 in patient tissues and cancer cell lines. In patient samples, ANKRD49 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD49 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
